Victoza (Novo Nordisk)


Welcome to the PulseAid listing for the Victoza drug offered from Novo Nordisk. This GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [Chemical/Ingredient],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Novo Nordisk
NON-PROPRIETARY NAME: liraglutide
SUBSTANCE NAME: LIRAGLUTIDE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: GLP-1 Receptor Agonist [EPC],Glucagon-Like Peptide 1 [Chemical/Ingredient],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
ROUTE: SUBCUTANEOUS
DOSAGE FORM: INJECTION
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2010-01-25
END MARKETING DATE: 0000-00-00


Victoza HUMAN PRESCRIPTION DRUG Details:

Item DescriptionVictoza from Novo Nordisk
LABELER NAME: Novo Nordisk
DEA SCHEDULE:
ACTIVE STRENGTH: 6(mg/mL)
START MARKETING DATE: 2010-01-25
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0169-4060_59b63a67-32b7-4f89-b93a-40136efcd501
PRODUCT NDC: 0169-4060
APPLICATION NUMBER: NDA022341

Other LIRAGLUTIDE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Novo NordiskSaxenda